Pharma Research and Early Development (pRED)
Grenzacherstrasse 124
CH-4070 Basel
Switzerland

roche.com

Project leader

Mr. Martin Graf IMI StemBANCC Coordinator Head of Stem Cell Platform Discovery Technologies E-Mail

Project staff

Dr. Nicole Clemann WP10 co-leader Non Clinical Safety E-Mail

Dr. Mark Burcin WP3 co-leader Lab Leader, Stem Cell Platform Discovery Technologies E-Mail

Mr. Klaus Christensen WP03 Lab Leader, Stem Cell Platform Discovery Technologies E-Mail

Dr. Ravi Jagasia WP08 - CNS Lab Leader, Neuroscience Discovery E-Mail

Dr. Hansruedi Loetscher WP08 - CNS Head Molecular Neuroscience Neuroscience Discovery E-Mail

Dr. Anna-Lisa Gündner WP08 - CNS Post Doc, Neuroscience Discovery E-Mail

Dr. Roberto Iacone WP09 - Diabetes Group Leader, Cardiovascular & Metabolic Diseases E-Mail

Dr. Osele Ciampi WP09 WP10  Post Doc, Cardiovascular & Metabolic Diseases E-Mail

Institute presentation

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2011, Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 42.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.